Basic information Supplier

Duteplase

Basic information Supplier
120608-46-0 Basic informationMore
USE
Duteplase, a nearly pure double-chain recombinant tissue-type plasminogen activator (rt-PA), was introduced in Japan for the treatment of acute myocardial infarction. Similar to other thrombolytic agents, duteplase acts by converting the proenzyme plasminogen to the active enzyme plasmin, resulting in fibrinolysis and varying degrees of depletion of circulating fibrinogen, factor V and factor VIII. In patients with acute myocardial infarction, treatment with duteplase induced patency rate of infarct-related artery at 90 minutes by up to 69%. Compared with alteplase, a single-chain rt-PA, duteplase has similar activity but a slower clearance rate and thus lower doses of duteplase have a similar therapeutic effect to alteplase.

Browse by Nationality 120608-46-0 Suppliers >Global suppliers

Other (1) All (1)
Please select the suppliers
Recommend You Select Member Companies
  • Company Name:Lanospharma Laboratories Co.,Ltd
  • Tel:13440048448
  • Products Intro:
  • CB Index:56
  • Related Information:Catalog(6343)
  •